Photo of Robert J. Mayer,  MD

Robert J. Mayer, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3474
Fax: (617) 632-2260

Robert J. Mayer, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Stephen B. Kay Family Professor of Medicine, Medicine, Harvard Medical School
  • Attending Physician, MGH Cancer Center, Massachusetts General Hospital
  • Consulting Staff, Medicine, Beth Israel Deaconess Medical Center
  • Senior Physician, Medicine, Brigham And Women's Hospital
  • Faculty Vice President for Academic affairs, Medical Oncology, Dana-Farber Cancer Institute
  • Faculty Associate Dean, Admissions, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

DF/HCC ASSOCIATIONS

  • Member, Center Scientific Council

Research Abstract

Gastrointestinal cancer ranks second only to respiratory cancer in the number of new cases and annual deaths in the United States each year. The term gastrointestinal cancer refers to malignant conditions of the esophagus, stomach, liver, biliary system, pancreas, small bowel, large bowel (i.e., colon and rectum), and anus.



Our efforts include the identification and counseling of families at high risk of developing such disorders, the study of medical interventions to prevent the diseases, screening techniques to detect them at a preclinical stage, and the development of innovative treatment plans for diagnosed patients. Such efforts involve the participation of medical, radiation, and surgical oncologists, pathologists, gastroenterologists, social workers, and genetic counselors.



The Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B, chaired by Dr. Mayer, is a multi-institutional collaboration supported by the National Cancer Institute. This research organization designs clinical trials conducted at DFCI and elsewhere throughout the United States.



Our work has been instrumental in studies which have defined optimal post-surgical (i.e. adjuvant) treatment for colon and rectal cancer and newer approaches to localized and advanced pancreatic cancer. In addition, Dr. Mayer has brought such new compounds as cetuximab to Dana-Farber for clinical testing.

Publications

Powered by Harvard Catalyst
  • Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, . Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372:1909-19. PubMed
  • Bohanes P, Rankin CJ, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martensen JA, Benson AB, Mayer RJ, Cripps CM, Danenberg K, Makar KW, Zhang W, Benedetti JK, Lenz HJ. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res 2015; 21:1583-90. PubMed
  • Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. Journal of the National Cancer Institute 2014; 107:345. PubMed
  • Mayer RJ, Venook AP, Schilsky RL. Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. J Clin Oncol 2014. PubMed
  • Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS ONE 2014; 9:e99816. PubMed
  • Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, . Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. Journal of the National Cancer Institute 2013; 105:1789-98. PubMed
  • Burt RW, Cannon JA, David DS, Early DS, Ford JM, Giardiello FM, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Jasperson K, Klapman JB, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Dwyer M, Freedman-Cass D. Colorectal cancer screening. J Natl Compr Canc Netw 2013; 11:1538-75. PubMed
  • Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 2013; 12:233-8. PubMed
  • Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys 2013; 87:638-45. PubMed
  • Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res 2013; 19:5777-87. PubMed
  • Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol 2013. PubMed
  • Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS. Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. Journal of the National Cancer Institute 2012; 104:1702-11. PubMed
  • Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin. J Clin Oncol 2012. PubMed
  • Dillmon M, Goldberg JM, Ramalingam SS, Mayer RJ, Loehrer P, Van Poznak C. Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist. J Oncol Pract 2013; 8:350-3, 2 p following 353. PubMed
  • Mayer RJ. Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol 2012; 30:3325-7. PubMed
  • Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS, . A phase 2 trial of gemcitabine, 5-florouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer 2010. PubMed
  • Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Fuchs CS. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2010; 28:4354-63. PubMed
  • Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 2010; 116:4007-13. PubMed
  • Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28:3617-22. PubMed
  • Mayer RJ. By the way, doctor. I read that President Obama had a virtual colonoscopy. Is this the colon cancer screening test that everybody should be getting instead of a regular colonoscopy? I thought it was kind of experimental. Harv Health Lett 2010; 35:8. PubMed
  • Wolpin BM, Mayer RJ. A step forward in the treatment of advanced biliary tract cancer. N Engl J Med 2010; 362:1335-7. PubMed
  • King JC, Lawrence TS, Murphy SB, Davidson NE, Mayer RJ. The american society of clinical oncology cancer foundation grants program: a 25-year report and a look toward the future. J Clin Oncol 2010; 28:1616-21. PubMed
  • Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton SR, Ismail MK, Jasperson K, Lazenby AJ, Lynch PM, Martin EW, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, . NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010; 8:8-61. PubMed
  • Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS, , , , . KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15:7322-9. PubMed
  • Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 2009; 27:5506-12. PubMed
  • Mayer RJ. By the way, doctor. We have screening tests for other cancers. How about pancreatic cancer? Harv Health Lett 2009; 34:1. PubMed
  • Bertagnolli MM,Niedzwiecki D,Compton CC,Hahn HP,Hall M,Damas B,Jewell SD,Mayer RJ,Goldberg RM,Saltz LB,Warren RS,Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27:1814-21. PubMed
  • Harsha HC,Kandasamy K,Ranganathan P,Rani S,Ramabadran S,Gollapudi S,Balakrishnan L,Dwivedi SB,Telikicherla D,Selvan LD,Goel R,Mathivanan S,Marimuthu A,Kashyap M,Vizza RF,Mayer RJ,Decaprio JA,Srivastava S,Hanash SM,Hruban RH,Pandey A. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009; 6:e1000046. PubMed
  • Bertagnolli MM,Warren RS,Niedzwiecki D,Mueller E,Compton CC,Redston M,Hall M,Hahn HP,Jewell SD,Mayer RJ,Goldberg RM,Saltz LB,Loda M. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res 2009; 15:2116-22. PubMed
  • Ajani JA,Winter KA,Gunderson LL,Pedersen J,Benson AB 3rd,Thomas CR Jr,Mayer RJ,Haddock MG,Rich TA,Willett CG. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol 2009; 27:1116-21. PubMed
  • Mayer RJ. Targeted therapy for advanced colorectal cancer--more is not always better. N Engl J Med 2009; 360:623-5. PubMed
  • Neubauer A,Maharry K,Mrozek K,Thiede C,Marcucci G,Paschka P,Mayer RJ,Larson RA,Liu ET,Bloomfield CD. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26:4603-9. PubMed
  • Meyerhardt JA,Niedzwiecki D,Hollis D,Saltz LB,Mayer RJ,Nelson H,Whittom R,Hantel A,Thomas J,Fuchs CS. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 2008; 26:4109-15. PubMed
  • Meropol NJ,Niedzwiecki D,Shank B,Colacchio TA,Ellerton J,Valone F,Budinger S,Day JM,Hopkins J,Tepper J,Goldberg RM,Mayer RJ. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 2008; 26:3229-34. PubMed
  • Chan JA,Meyerhardt JA,Niedzwiecki D,Hollis D,Saltz LB,Mayer RJ,Thomas J,Schaefer P,Whittom R,Hantel A,Goldberg RM,Warren RS,Bertagnolli M,Fuchs CS. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA 2008; 299:2515-23. PubMed
  • Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134:1296-310. PubMed
  • Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008; 299:1914-21. PubMed
  • Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26:1086-92. PubMed
  • Propert KJ, Mayer R, Nickel JC, Payne CK, Peters KM, Teal V, Burks D, Kusek JW, Nyberg LM, Foster HE. Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo. J Urol 2007; 179:552-5. PubMed
  • Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2007; 26:313-25. PubMed
  • Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2007; 60:661-70. PubMed
  • Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 25:4165-7. PubMed
  • Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007; 298:754-64. PubMed
  • Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25:3456-61. PubMed
  • Meyerhardt J, Stuart K, Fuchs C, Zhu A, Earle C, Bhargava P, Blaszkowsky L, Enzinger P, Mayer R, Battu S, Lawrence C, Ryan D. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Ann Oncol 2007; 18:1185-9. PubMed
  • Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57:168-85. PubMed
  • Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ,. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2006; 25:146-62. PubMed
  • Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2006; 132:127-38. PubMed
  • Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914-21. PubMed
  • Goessling W, Mayer RJ. Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35:713-27. PubMed
  • Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006; 24:3535-41. PubMed
  • Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24:3542-7. PubMed
  • Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from cancer and leukemia group B 8461. Blood 2006; 108:63-73. PubMed
  • Larson RA, Stone RM, Mayer RJ, Schiffer CA. Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res 2006; 12:3556s-63s. PubMed
  • Goldberg RM, Niedzwiecki D, Bertagnolli M, Blackstock AW, Tepper JE, Mayer RJ. Cancer and leukemia group B gastrointestinal cancer committee. Clin Cancer Res 2006; 12:3589s-95s. PubMed
  • Ryan DP, Niedzwiecki D, Hollis D, Mediema BE, Wadler S, Tepper JE, Goldberg RM, Mayer RJ. Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24:2557-62. PubMed
  • Levin B, Barthel JS, Burt RW, David DS, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton S, Kohlmann W, Ludwig KA, Lynch PM, Marino C, Martin EW Jr, Mayer RJ, Pasche B, Pirruccello SJ, Rajput A, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Winawer SJ. Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw 2006; 4:384-420. PubMed
  • Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395-403. PubMed
  • Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JM, Bem J, Mayer RJ, Bertagnolli MM,. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol 2006; 24:878-83. PubMed
  • Mayer RP, Stowe RA. Packed uniform sphere model for solids: Interstitial access opening sizes and pressure deficiencies for wetting liquids with comparison to reported experimental results. J Colloid Interface Sci 2005; 294:139-50. PubMed
  • Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ,. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2005; 24:190-205. PubMed
  • Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23:8706-12. PubMed
  • Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2006; 50:2218-23. PubMed
  • Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23:8671-8. PubMed
  • Sminia P, Mayer R, van der Kleij A, Feldmeier J. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy: In regard to Anscher et al. (Int J Radiat Oncol Biol Phys 2005;62:255-259). Int J Radiat Oncol Biol Phys 2005; 63:649-50; author reply 650. PubMed
  • Mayer R, Sminia P, McBride WH, Stranzl H, Prettenhofer U, Fruhwirth J, Poschauko J. Lymphatic fistulas: obliteration by low-dose radiotherapy. Strahlenther Onkol 2005; 181:660-4. PubMed
  • Higashitsuji H, Liu Y, Mayer RJ, Fujita J. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation. Cell Cycle 2005; 4:1335-7. PubMed
  • Marcucci G, Mr. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23:5705-17. PubMed
  • Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, Sumitomo H, Masuda T, Dawson S, Shimada Y, Mayer RJ, Fujita J. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005; 8:75-87. PubMed
  • Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, Culkin DJ, Diokno A, Hanno P, Landis JR, Madigan R, Messing EM, Nickel JC, Sant GR, Warren J, Wein AJ, Kusek JW, Nyberg LM, Foster HE,. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol 2005; 173:1186-91. PubMed
  • Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23:1819-25. PubMed
  • Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87. PubMed
  • Farag SS, Ruppert AS, Mr. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2004; 23:482-93. PubMed
  • Devoy A, Soane T, Welchman R, Mayer RJ. The ubiquitin-proteasome system and cancer. Essays Biochem 2005; 41:187-203. PubMed
  • Lowe J, Hand N, Mayer RJ. Application of ubiquitin immunohistochemistry to the diagnosis of disease. Methods Enzymol 2005; 399:86-119. PubMed
  • Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004; 112:754-9. PubMed
  • McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004; 27:485-8. PubMed
  • Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64:3014-21. PubMed
  • Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8. PubMed
  • Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004; 22:353-9. PubMed
  • Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther 2004; 3:73-8. PubMed
  • Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol 2004; 22:166-74. PubMed
  • Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349:2241-52. PubMed
  • Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med 2003; 139:649-57. PubMed
  • Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB, Macdonald JS, Fuchs CS. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003; 98:484-95. PubMed
  • Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 2003; 63:1608-14. PubMed
  • Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21:433-40. PubMed
  • Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest 2003; 21:505-11. PubMed
  • Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8:395-9. PubMed
  • McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002; 94:1160-7. PubMed
  • Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002; 94:3186-91. PubMed
  • Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, Haller DG. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002; 136:261-9. PubMed
  • Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94:97-103. PubMed
  • Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer RJ, Clark JW. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer 2000; 88:180-5. PubMed
  • Mayer RJ. Pancreatic cancer. RNA Biol 2005; In press:537-9.
  • Mayer RJ. Gastrointestinal tract cancer. J Am Diet Assoc 2005; In press:523-9.
  • Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858-68. PubMed
  • Silverman SG, Khorasani R, Adams DF, Phillips MD, Sica GT, Mayer RJ. Multidisciplinary gastrointestinal cancer clinic: abdominal radiologist as active participant. Acad Radiol 1998; 5:694-7. PubMed
  • Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112:594-642. PubMed
  • O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-50. PubMed
  • Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and rectal cancer. Semin Oncol 1995; 22:472-87. PubMed
  • Mayer RJ. Summary of the Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Ann Oncol 1995; 6:645-9. PubMed
  • Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32-41. PubMed
  • Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896-903. PubMed
Hide